Sphere Bio

Sphere Bio is a private, platform-technology company that has developed the Cyto-Mine® suite of instruments and reagents for high-throughput single-cell screening and isolation. Its core technology uses biocompatible picodroplets to encapsulate individual cells, allowing for the gentle analysis of millions of cells per day to identify rare, high-producing clones for biologics development. The company appears to be in an early-revenue stage, selling its platforms and consumables to biopharma and research clients, and was recently acquired by Fluidic Sciences, integrating it into a broader portfolio. Sphere Bio's solutions address critical bottlenecks in drug discovery, aiming to reduce timelines and increase confidence in cell selection.

Proprietary picodroplet microfluidic technology for high-throughput single-cell encapsulation, multiplexed analysis, and isolation with monoclonality assurance.

Sphere Bio competes in the single-cell analysis and isolation market against companies like Berkeley Lights (nanowell technology), 10x Genomics (barcoding for genomics), and traditional methods like FACS and limiting dilution. Its differentiation lies in the gentle, high-throughput picodroplet microfluidics approach combined with integrated monoclonality documentation.